Effects of gastric inhibitory polypeptide, glucagon‐like peptide‐1 and glucagon‐like peptide‐1 receptor agonists on Bone Cell Metabolism

Publisher： John Wiley & Sons Inc

E-ISSN： 1742-7843|122|1|25-37

ISSN： 1742-7835

Source： BASIC AND CLINICAL PHARMACOLOGY & TOXICOLOGY (ELECTRONIC), Vol.122, Iss.1, 2018-01, pp. : 25-37

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular risk factors: A narrative review of head‐to‐head comparisons

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 3, 2018-03 ,pp. : 508-519

John Wiley & Sons Inc

Access to resources Recommend Favorite

Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Type 2 diabetes

By Ross Stuart A.   Ballantine Jane  

Current Medical Research and Opinion, Vol. 29, Iss. 12, 2013-12 ,pp. : 1617-1626

Informa Healthcare

Access to resources Recommend Favorite

Xenopus‐derived glucagon‐like peptide‐1 and polyethylene‐glycosylated glucagon‐like peptide‐1 receptor agonists: long‐acting hypoglycaemic and insulinotropic activities with potential therapeutic utilities

By  

BRITISH JOURNAL OF PHARMACOLOGY (ELECTRONIC), Vol. 175, Iss. 3, 2018-02 ,pp. : 544-557

John Wiley & Sons Inc

Access to resources Recommend Favorite

Glucagon‐like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 4, 2015-04 ,pp. : 335-342

John Wiley & Sons Inc

Access to resources Recommend Favorite

Overnight hypoxic exposure and glucagon-like peptide-1 and leptin levels in humans

By Snyder Eric M.   Carr Richard D.   Deacon Carolyn F.   Johnson Bruce D.  

Applied Physiology, Nutrition, and Metabolism, Vol. 33, Iss. 5, 2008-10 ,pp. : 929-935

NRC Research Press

Access to resources Recommend Favorite